Inogen (INGN) Given a $258.00 Price Target at Stifel Nicolaus


The brokerage currently has a "buy" rating on the medical technology company's stock. Stifel Nicolaus' price target would suggest a potential upside of 10.41% from the company's current price.



from Biotech News